Welcome to our dedicated page for Celldex Therapeutics news (Ticker: $CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celldex Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celldex Therapeutics's position in the market.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported Q1 2024 financial results and a corporate update. Phase 3 CSU studies to start in summer 2024. Positive Phase 2 CSU 12-week data presented at AAAAI 2024, with 52-week data to follow later. Phase 2 CIndU study enrollment completed, with Phase 2 PN study ongoing. Atopic dermatitis selected for Phase 2 study by YE 2024. Cash position at $823.8 million. Total revenue at $0.2 million. R&D expenses at $31.7 million. G&A expenses at $9.1 million. Net loss at $32.8 million.
